Business / Finance RSS Feed - Business / Finance

DePuy Synthes inks sales agreement with Radlink to offer real-time image guidance with hip replacement systems

DePuy Synthes inks sales agreement with Radlink to offer real-time image guidance with hip replacement systems

DePuy Synthes Companies has signed an exclusive worldwide sales agreement with Radlink, Inc., an emerging global leader in advanced medical imaging technology, to offer real-time image guidance with its hip replacement systems. The agreement further demonstrates DePuy Synthes Companies’ ongoing commitment to help improve patient outcomes, increase patient satisfaction and reduce costs. [More]
Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao. [More]

Philips enters into collaboration with Janssen to develop new handheld blood test to support care of patients with neuropsychiatric disorders

Royal Philips today announced that it has entered into a multi-year development agreement with Janssen Pharmaceutica N.V. (Janssen). [More]

Nanolek, Green Cross sign strategic deal to commercialize biologics in the Russian market

Green Cross, a South Korean biopharmaceutical company, and Nanolek, a Russian pharmaceutical company, today announced that they have entered into a strategic partnership agreement for the commercialisation of Green Cross' biologics in the Russian market. [More]
Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014. [More]
AstraZeneca, HSCI collaborate to find new treatments for diabetes

AstraZeneca, HSCI collaborate to find new treatments for diabetes

AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes. [More]
C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company’s current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies’ portfolio. [More]
Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation, a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020. [More]
Lycera achieves milestone in Merck research collaboration

Lycera achieves milestone in Merck research collaboration

Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment. [More]

Pentax Medical announces new chief marketing officer and Americas region president

David Woods, the current president of PENTAX Medical of the Americas, has been appointed as the new global Chief Marketing Officer (CMO), effective April 1, 2015... [More]
Vermillion announces total revenue of $1.6 million for fourth quarter 2014

Vermillion announces total revenue of $1.6 million for fourth quarter 2014

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter ended and full year ended December 31, 2014. [More]

Sun Pharma closes Ranbaxy merger

Sun Pharmaceutical Industries Ltd., today, begins the integration of Ranbaxy's business following the successful closure of its merger. [More]
Omnicell receives notification from NASDAQ OMX Group for noncompliance with Nasdaq Listing Rule

Omnicell receives notification from NASDAQ OMX Group for noncompliance with Nasdaq Listing Rule

As indicated in a Form 8-K filed with the SEC on March 20, 2015, Omnicell, Inc. received a written notification from the NASDAQ OMX Group, Inc. on March 18, 2015, indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) for continued listing, due to the delay in filing its Annual Report on Form 10-K for the period ended December 31, 2014 beyond the extended filing due date of March 17, 2015. [More]
Beaumont Health joins UHC and Novation to increase cost savings, improve supply chain performance

Beaumont Health joins UHC and Novation to increase cost savings, improve supply chain performance

UHC announced today that Beaumont Health has partnered with UHC and its supply contracting company, Novation, on a new two-year initiative designed to increase cost savings and supply chain performance improvement. [More]

Funding helps researchers to kiss MS goodbye

Murdoch University researchers have received funding to investigate the link between the Epstein-Barr virus infection, more commonly known as glandular fever or the ‘kissing disease’, and the debilitating disease Multiple Sclerosis (MS). [More]

Confluence pharmaceuticals signs co-development and marketing agreement with AOP orphan for fragile X syndrome drug

Confluence is a biopharmaceutical company focused on developing therapeutic treatments for Fragile X Syndrome and Autism Spectrum Disorders. AOP is an Austrian based company specializing in the development and marketing of medicines for rare and complex diseases. [More]
Dipexium Pharmaceuticals reports strong financial results for year ended December 31, 2014

Dipexium Pharmaceuticals reports strong financial results for year ended December 31, 2014

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced operational, clinical and financial results for the year ended December 31, 2014. [More]
GenVec reports record financial results for Q4 and fiscal year 2014

GenVec reports record financial results for Q4 and fiscal year 2014

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the year ended December 31, 2014, the company reported a net loss of $2.5 million, or $0.16 per share, compared with a net loss of $10.0 million, or $0.77 per share, for the year ended December 31, 2013. [More]
Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. [More]
Myriad announces Prolaris® test biopsy results from EMPATHY-P study at European Association of Urology annual meeting

Myriad announces Prolaris® test biopsy results from EMPATHY-P study at European Association of Urology annual meeting

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. [More]
Advertisement
Advertisement